
uniQure 宣布 AMT-130 基因疗法治疗亨廷顿氏病的 I/II 期临床试验最新进展
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean